This is the world's first system to non-invasively treat patients with cardiac radiosurgery in Asia.
"We are excited to offer our patients the most advanced, painless and non-invasive treatment for cardiovascular conditions, and thrilled to be the first center in Asia to offer the use of this breakthrough technology," said Jun Itami, MD, PhD, and chair of the Department of Radiation Oncology, National Cancer Center.
"The CyberHeart System allows patients to undergo ablation for cardiac arrhythmias and other vascular conditions as an outpatient. The personalized nature of the ablation allows the treatment to be tailored to the patient's individual anatomy."
NCC expects to begin treating patients shortly, and intends to develop various treatment protocols and subsequently publish their research.
"A non-invasive treatment approach to cardiac arrhythmias should significantly benefit patients with and without malignancy, and clearly enhance their quality of life," said Masaaki Shoji, MD, cardiologist at NCC.
"The installation at NCC is the beginning of international activity for CyberHeart, as this therapy is embraced by physicians in the treatment of cardiac conditions," said Patrick Maguire, MD, PhD, President and CEO of CyberHeart. "We are delighted to work with this world-class institution to broaden the scope of therapy and bring it to additional patients."
CyberHeart is a privately held medical device company located at The Fogarty Institute for Innovation in Mountain View, Calif. The company is focused on the development of radiosurgery for cardiovascular conditions.
The CyberHeart System uses image-guided tracking of intra-cardiac and other ablation targets, so clinicians can contour and target ablation sites specific to a given patient's anatomy.
It is the world's first non-invasive robotic assisted ablation treatment for cardiac conditions. CyberHeart™ and CardioPlan™ are registered trademarks of CyberHeart Inc.
